- Reviva Pharmaceuticals Holdings Inc RVPH is trading higher with around 60k in session volume.
- Maxim initiated coverage of Reviva with a Buy rating and $10 price target, equivalent to an upside of around 140%.
- The company is developing its lead asset, RP5063 (brilaroxazine), to treat schizophrenia and respiratory indications.
- Analyst Jason McCarthy tells in a research note that RP5063 features a multimodal mechanism of action, which is "more completely" addressing the mix of positive, negative, and cognitive symptoms associated with schizophrenia.
- In April, RP5063 showed positive action in the schizophrenia trial that met its primary endpoint of disease severity versus placebo.
- Price Action: RVPH shares are up 9.92% at $4.21 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
